Australia markets open in 9 hours 7 minutes

Aditxt, Inc. (ADTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.1730+0.0016 (+0.93%)
As of 10:52AM EDT. Market open.

Aditxt, Inc.

737 North Fifth Street
Suite 200
Richmond, VA 23219
United States
909 488 0844
https://www.aditxt.com

Sector(s):Β Healthcare
Industry:Β Biotechnology
Full-time employees:Β 58

Key executives

NameTitlePayExercisedYear born
Mr. Amro A. AlbannaCo-Founder, Chairman & CEO750kN/A1970
Ms. Corinne D. Pankovcin CPA, CPA, M.B.A.Pres583.25kN/A1966
Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D.Co-Founder, Chief Innovation Officer, Sec. & Director455kN/A1963
Mr. Thomas J. Farley CPAChief Financial Officer522kN/A1973
Ms. Rowena AlbannaChief Operating OfficerN/AN/A1966
Mr. Matthew M. ShatzkesChief Legal Officer & Gen. CounselN/AN/AN/A
Ms. Jennifer LeeDirector of HRN/AN/AN/A
Dr. Dolly B. Tyan Ph.D.Sr. VP of Clinical Devel. Β– TransplantationN/AN/AN/A
Dr. Joachim-Friedrich Kapp M.D., Ph.D.Sr. VP of Clinical Devel. - AutoimmunityN/AN/A1942
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

Corporate governance

Aditxt, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.